SPOTLIGHT -
Presented by Joseph J. Del Pizzo, MD, New York Presbyterian Hospital
Galen Prostate demonstrates diagnostic value in prostate cancer
Overall, participating pathologists felt that there is potential to increase diagnostic efficiency by using Galen Prostate in a clinical setting.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
Urobiome community type linked with more severe incontinence episodes
Tepidimonas was notably associated with more severe urinary incontinence episodes, suggesting a potential marker for identifying individuals at risk for more severe symptoms.
Dr. Murphy on increasing diversity in cancer clinical trials
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
FDA grants orphan drug designation to ADV7103 for cystinuria
ADV7103 is currently being studied in the phase 2/3 CORAL-1 study, enrolling patients with cystinuria across centers in France and Belgium.
National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders
Developed by the AUGS Scientific Committee and Research Agenda Writing Group